Arch Scientist Publishes Data on the Pre-Clinical Efficacy of AB569 in Killing of Drug Resistant Bacteria A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9328b8b7-9f45-4361-915c-3a569b3716a0 TORONTO, Feb. 21, 2020 (GLOBE NEWSWIRE) --  Arch...

Arch Biopartners Announces Issuance of U.S. Patent for Its Novel Antibacterial Drug AB569, Designed to Target Chronic Infection and Antibiotic Resistance TORONTO, March 27, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF), announced today that the U.S. Patent and Trademark Office has issued U.S....